Skip to main content

Table 1 (abstarct P06). Baseline characteristics and third interim analysis data of patients with FMF

From: Abstracts from the ISSAID 2021 Periodic Congress

  Baseline 6 months 18 months
All patients | Patients without prior CAN therapy All patients Patients without prior CAN All patients Patients without prior CAN All patients Patients without prior CAN
Number of patients, N 54 11 35 7 16 3
Number (%*) of patients in disease remission (physician assessment) 18   (48.6) 1         (20.0) 19          (73.1) 3          (75.0) 8        (61.5) 1        (100.0)
Patient assessment of current disease activity; 0–10, median (min; max) 3.0          (0; 10) 7.0           (0; 10) 2.5                 (0; 7) 2.0              (0; 5) 2.0               (0; 6) 0.5               (0; 1)
Patient assessment of current fatigue; 0–10, median (min; max) 5.0         (0; 10) 5.0           (0; 9) 3.5                    (0; 10) 3.0             (1; 6) 3.0               (0; 7) 0.5               (0; 1)
Number (%*) of patients without impairment of social life by the disease 19      (46.3) 3                 (37.5) 18                       (66.7) 3                 (75.0) 5               (55.6) 2                 (66.7)
CRP/SAA, median (mg/dl) 0.2/0.7 1.1/6.8 0.2/0.8 0.1/0.4 0.1/0.6 0.5/0.7
  1. *not reported for all patients
  2. CRP, c-reactive protein; SAA, serum amyloid A